DOI: 10.1128/IAI.00303-17
Article Information
PubMed
Published By
History
- Received April 28, 2017
- Returned for modification June 6, 2017
- Accepted July 24, 2017
- Published online September 20, 2017.
Copyright & Usage
Copyright © 2017 American Society for Microbiology.
All Rights Reserved
.
Editors and / or Reviewers
- Vincent B. Young, Editor, University of Michigan—Ann Arbor
Article Versions
- Accepted Manuscript version (July 31, 2017).
- You are viewing the most recent version of this article.
Author Information
- Jennifer K. Spinlera,b,
- Jennifer Auchtungc,
- Aaron Browna,b,
- Prapaporn Boonmaa,b,
- Numan Oezguena,b,
- Caná L. Rossa,b,
- Ruth Ann Lunaa,b,
- Jessica Rungea,b,
- James Versalovica,b,
- Alex Peniched,
- Sara M. Dannd,
- Robert A. Brittonc,
- Anthony Haaga,b and
- Tor C. Savidgea,b
- aDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA
- bTexas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas, USA
- cAlkek Center for Metagenomics & Microbiome Research, Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, USA
- dDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
- Address correspondence to Jennifer K. Spinler, spinler{at}bcm.edu.
Citation Spinler JK, Auchtung J, Brown A, Boonma P, Oezguen N, Ross CL, Luna RA, Runge J, Versalovic J, Peniche A, Dann SM, Britton RA, Haag A, Savidge TC. 2017. Next-generation probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect Immun 85:e00303-17. https://doi.org/10.1128/IAI.00303-17 .
